Here's the deal with hormone receptor-positive breast cancer: a lot of these tumors are basically estrogen freeloaders. They sense the hormone, they grab it, they grow. So the obvious move is to cut off the supply. For decades, the standard tool was tamoxifen, a drug that crashes the estrogen party by blocking the receptor.
But what if you went further? What if you also shut down the ovaries themselves, the estrogen factory? That's ovarian function suppression, or OFS. And what if, on top of that, you swapped tamoxifen for exemestane, an aromatase inhibitor that mops up estrogen production from other tissues too?
The SOFT and TEXT trials asked exactly that, enrolling over 5,700 premenopausal women and randomizing them to different combos: tamoxifen alone, tamoxifen plus OFS, or exemestane plus OFS. Then they waited. And waited. Fifteen years of waiting, which in oncology trial terms is roughly a geological era.
So who actually won?
If you want the bumper sticker: escalating the treatment kept paying off, but not equally for everyone.
In SOFT, the 15-year breast-cancer-free interval climbed as the therapy got more aggressive: 72.1% with tamoxifen alone, 75.7% with tamoxifen plus OFS, and 78.6% with exemestane plus OFS. Adding OFS to tamoxifen alone reduced events with a hazard ratio of 0.82. Combine SOFT and TEXT for HER2-negative tumors and exemestane plus OFS cut distant recurrence by a quarter (HR 0.75) compared to tamoxifen plus OFS. Distant recurrence is the scary kind, the cancer-packs-a-bag-and-moves-out kind, so that number matters.
But survival is where things get interesting, and a little humbling.
The plot twist nobody loves but everybody needed
Here's the part that should reshape how doctors think. The meaningful overall survival benefit from cranking up the treatment? It mostly showed up in the high-risk crowd. Young patients, high-grade tumors, the cases where the cancer was already playing dirty.
Look at women under 35 with HER2-negative tumors: 15-year survival was 82.5% with exemestane plus OFS versus a sobering 68.1% with tamoxifen alone. That's not a rounding error. That's a 14-point gap in whether someone is alive in fifteen years. For these young patients, tamoxifen by itself was leaving outcomes on the table.
Meanwhile, in the lower-risk no-chemotherapy cohort, survival stayed high no matter which arm patients landed in. Translation: if your cancer was the well-behaved, low-grade type, piling on more hormone-blocking didn't buy you much extra time, and OFS comes with real costs (hot flashes, bone loss, mood effects, the whole forced-menopause starter pack).
So the takeaway isn't "everyone needs the strongest combo." It's "match the intensity of the treatment to the intensity of the threat." Which sounds obvious until you remember medicine spent years treating these patients as one big group.
Why this is a quietly big deal
Tailoring is the whole game now. These final results basically hand oncologists a map: for premenopausal women with high-grade, HER2-negative tumors, tamoxifen-based therapy alone may not cut it, and the more aggressive approach earns its keep. For lower-risk patients, you can spare them the side effects without gambling with their survival.
Fifteen years of follow-up to land that nuance is the kind of patience that doesn't trend on social media but absolutely changes lives. The estrogen forecast, it turns out, depends entirely on which neighborhood of the breast you're standing in.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.
References
- Francis PA, Pagani O, Fleming GF, et al. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. Annals of Oncology. 2026. DOI: 10.1016/j.annonc.2026.05.704. PMID: 42229584.
- Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018;379:122-137. DOI: 10.1056/NEJMoa1803164. PMID: 29863451.
- Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med. 2014;371:107-118. DOI: 10.1056/NEJMoa1404037. PMID: 24881463.
- Francis PA, Regan MM, Fleming GF, et al. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med. 2015;372:436-446. DOI: 10.1056/NEJMoa1412379. PMID: 25495490.